Strs Ohio Iveric Bio, Inc. Transaction History

Strs Ohio

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 31, 2023	BUY	$26.24 - $39.63 $191,552 - $289,299	7,300 Added 27.65%	33,700 $1.33 Million
Q1 2023 Aug 02, 2023	SELL	$18.67 - $24.56 $136,291 - $179,288	-7,300 Reduced 21.66%	26,400 $642,000
Q1 2023 Apr 27, 2023	BUY	$18.67 - $24.56 $184,833 - $243,144	9,900 Added 60.0%	26,400 $642,000
Q4 2022 Jan 26, 2023	BUY	$17.24 - $23.95 $34,480 - $47,900	2,000 Added 13.79%	16,500 $353,000
Q3 2022 Oct 27, 2022	SELL	$9.4 - $18.59 $127,840 - $252,824	-13,600 Reduced 48.4%	14,500 $260,000
Q2 2022 Jul 25, 2022	SELL	$9.12 - $18.9 $10,032 - $20,790	-1,100 Reduced 3.77%	28,100 $270,000
Q1 2022 Apr 21, 2022	SELL	$12.15 - $16.83 $19,440 - $26,927	-1,600 Reduced 5.19%	29,200 $491,000
Q3 2021 Oct 22, 2021	BUY	$7.07 - $17.5 $52,318 - $129,500	7,400 Added 31.62%	30,800 $500,000
Q2 2021 Jul 26, 2021	BUY	$5.69 - $7.17 $12,518 - $15,774	2,200 Added 10.38%	23,400 $147,000
Q3 2020 Dec 14, 2020	SELL	$4.01 - $6.29 $57,744 - $90,576	-14,400 Reduced 40.45%	21,200 $119,000
Q2 2020 Jul 23, 2020	BUY	$3.06 - $6.6 $108,936 - $234,960	35,600 New	35,600 $181,000

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Strs Ohio, based on Form 13F filings with the SEC.

Stay updated on Strs Ohio with notifications on news.